Evolent Health (EVH) PT Set at $22.00 by Jefferies Group

Evolent Health (NYSE:EVH) received a $22.00 price target from stock analysts at Jefferies Group in a note issued to investors on Tuesday. The firm presently has a “buy” rating on the technology company’s stock. Jefferies Group’s price objective would suggest a potential upside of 57.71% from the stock’s previous close.

Several other analysts have also recently commented on EVH. Robert W. Baird reiterated a “buy” rating and set a $25.00 price target on shares of Evolent Health in a research report on Wednesday, November 1st. Cantor Fitzgerald reiterated a “buy” rating and set a $30.00 price target on shares of Evolent Health in a research report on Thursday, November 2nd. SunTrust Banks reiterated a “buy” rating and set a $30.00 price target on shares of Evolent Health in a research report on Friday, November 3rd. Goldman Sachs Group cut Evolent Health from a “conviction-buy” rating to a “buy” rating in a research report on Tuesday, November 7th. Finally, Leerink Swann set a $25.00 price target on Evolent Health and gave the stock a “buy” rating in a research report on Saturday, November 18th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $27.40.

Shares of Evolent Health (NYSE EVH) opened at $13.95 on Tuesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.34 and a current ratio of 3.34. Evolent Health has a 12-month low of $10.30 and a 12-month high of $27.50. The company has a market capitalization of $1,080.00 and a P/E ratio of -12.24.

Large investors have recently modified their holdings of the business. Omni Partners LLP purchased a new stake in Evolent Health in the 4th quarter valued at $820,000. Stifel Financial Corp acquired a new position in shares of Evolent Health in the 2nd quarter valued at $425,000. Kornitzer Capital Management Inc. KS acquired a new position in shares of Evolent Health in the 3rd quarter valued at $14,258,000. Alyeska Investment Group L.P. lifted its stake in shares of Evolent Health by 393.1% in the 3rd quarter. Alyeska Investment Group L.P. now owns 250,000 shares of the technology company’s stock valued at $4,450,000 after purchasing an additional 199,300 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Evolent Health in the 2nd quarter valued at $2,912,000. Institutional investors own 95.44% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://weekherald.com/2018/02/15/evolent-health-evh-pt-set-at-22-00-by-jefferies-group.html.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply